Summary
YEARS OF DOING SKIN SURGERY, TREATING KELOIDS IN PATIENTS HAVE DEMONSTRATED A NEED FOR A KELOID PREVENTING MODALITY. AZX100 SHOULD BE STUDIED, IF IT HAS NOT ALREADY BEEN, IN PATIENTS PRONE TO KEOIDS WHO NEED FURTHER SKIN SURGERY. THIS GIVE US AN EXCELLENT REPRODUCIBLE CLINICAL MODEL WITH A VISIBLE AND CONTROLLED END POINT.
Analysis
YEARS OF DOING SKIN SURGERY, TREATING KELOIDS IN PATIENTS HAVE DEMONSTRATED A NEED FOR A KELOID PREVENTING MODALITY. ONE SUCH STUDY, BUT NOT THE ONLY ONE, COULD BE DESIGNED TO USE PATIENTS WITH PREXISTING KELOIDS WHO NEED FURTHER CUTANEOUS SURGERY. THEY COULD THEN SERVE AS THEIR OWN CONTROL, HAVING HAD A PREXISTING KELOID AND NOW HAVING SURGERY WITH AZX100 (OR PLACEBO) AND BEING OBSERVED FOR THE NATURE OF THE HEALING, I.E. WITH OR WITHOUT A KELOID. SUCH SURGERY WOULD BE MORE BENIGN THAN SHOULDER ARTHROSCOPY AND EASIER TO EVALUATE. THERE ARE A LARGE NUMBER OF SUCH PATIENTS.
